Drugs / F61
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05483504 Comparator | Aug → Dec 2022 | COVID-19 | Wuhan Institute of Biological Products Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F61 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05483504 ↗ |
| Route | Intravenous | “single-dose ascending intravenous infusion of F61 in healthy subjects” NCT05483504 ↗ |